BOSTON , April 06, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced participation in the upcoming Needham 20th Annual Healthcare Conference on April 12-15 .

– Dosed first patients in Phase 1 study with new product candidate A3907 – – First patient dosed in ASSERT global Phase 3 study of odevixibat for Alagille syndrome – – EMA & FDA reviewing odevixibat for PFIC, currently no plans for FDA advisory committee meeting – – Achievement of important

– Calls to unite global communities affected by rare diseases – – Albireo supports increasing education and advances in research for rare cholestatic liver diseases – BOSTON , Feb. 26, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma , Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company

– NDA and MAA for odevixibat accepted, on track for anticipated H2 21 launch – – Announces odevixibat co-promotion agreement with Travere, a leading rare disease company – – ASSERT global pivotal Phase 3 trial in Alagille syndrome initiated and enrolling – – BOLD global pivotal Phase 3 study in

BOSTON , Feb. 23, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare pediatric liver disease company developing novel bile acid modulators, today announced participation in the upcoming Cowen 41st Annual Health Care Conference   March 1-4, 2021 .

Conference call and webcast to be held at 10:00 a.m. ET BOSTON , Feb. 18, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live

BOSTON , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo’s common stock.

– Company outlining large global rare cholestatic liver disease opportunity – – Advancing plans for anticipated odevixibat U.S. and EU launch, with focus on market access – – Expansion opportunity beyond PFIC and beyond odevixibat – – Commercial management to host conference call and webcast today

- Company receives FDA Priority Review with PDUFA date set for July 20, 2021 - - Submission data for PFIC types 1, 2, 3, supporting once-daily use across a wide range of patients - - FDA has granted odevixibat Fast Track, Rare Pediatric Disease and Orphan Drug Designations - - Odevixibat on track

Albireo supports the Alagille syndrome community to advocate for more education and new treatment advances for rare cholestatic liver diseases BOSTON , Jan. 22, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma , Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid